The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Scienmag

SEPTEMBER 28, 2020

The research shows how the molecular structure and sequence of the SARS-CoV-2 spike protein–part of the virus that causes […]. lu PITTSBURGH, Sept.

Protein 64

Protein Medicine Development Research 64

XTalks

NOVEMBER 30, 2023

Over the last 35 years, substantial strides have been made in tackling HIV/AIDS, propelled by advancements in medical research, enhanced accessibility to treatment and prevention and a more comprehensive understanding of the virus. World AIDS Day offers an occasion for reflection on the strides achieved thus far.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

FEBRUARY 22, 2021

Bayer’s research collaboration with the French biotech company Meiogenix is also accelerating the development of proprietary technologies related to plant breeding and genome editing applications. At Oerth Bio, we’re doing that by bridging a revolutionary therapeutic platform called PROTAC ® protein degraders into agriculture.”.

Gene Editing 40

Gene Editing Genome Genomics Protein 40

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. But 10% of the cases are caused by genetic factors, meaning patients inherit the condition through familial links. Adding to this, the infectivity of prion diseases also makes research challenging, says Wille.

Drugs 299

Drugs Protein Vaccination Vaccine 299

The Pharma Data

MARCH 24, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. AstraZeneca will also submit the primary analysis for peer-reviewed publication in the coming weeks.

Radiology 52

Radiology Vaccination Vaccine Trials 52

The Pharma Data

MARCH 22, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. D8110C00001 1. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial.

Trials 52

Trials Vaccination Vaccine Radiology 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease. Next, the researchers tested the safety and efficacy of VSV-SUDV in macaques.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. Nutritional DNA testing helps in identifying foods that might lead to allergies or intolerance in an individual.

Genome 40

Genome Genomics Genetics Gene 40

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% President of Research and Development, Novavax. Novavax, Inc. efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly. remains the dominant variant.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

DECEMBER 24, 2020

However, for virologists like Lori Frappier, PhD, professor in the department of molecular genetics at the University of Toronto, the outbreak of SARS-CoV-2 was less of a surprise and more of an inevitability. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Vaccine Considerations.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

MAY 13, 2021

Preliminary data obtained through genetic sequencing suggest that the new outbreak was caused by the same virus strain also responsible for the 2014-2016 outbreak and was likely reintroduced by a survivor. Global Head, Global Public Health Research & Development, Johnson & Johnson. “We 115854), EBOVAC2 (grant nr.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

National Institute of Allergy and Infectious Diseases, Gov. “The virus is becoming more fit, and we’re like a deer in the headlights,” Dr. Eric Topol, head of Scripps Research Translational Institute, told the AP. In an online conference with Dr. Anthony Fauci, head of the U.S.

Vaccination 52

Vaccination Vaccine Genetics Protein 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. University of Oxford and AstraZeneca COVID-19 Vaccine. Drugs and Vaccines.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92